Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00823147 · ClinicalTrials.gov registry record · Phase 1

Pain Catastrophizing as a Cause for Systemic Inflammation

A Phase 1 study of Musculoskeletal Pain, sponsored by Beth Darnall, PhD.

Completed
Registry status
Phase 1
Development phase
93
Enrollment target
1
Study location

NCT00823147: Completed Phase 1 study of Musculoskeletal Pain, sponsored by Beth Darnall, PhD.

NCT00823147 is a Phase 1 study of Musculoskeletal Pain that has completed, run by Beth Darnall, PhD. The registered enrollment target is 93 participants, below the 153-participant average among 37 other Musculoskeletal Pain trials with a reported enrollment target (39% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00823147, a Phase 1 study of Musculoskeletal Pain, has completed, sponsored by Beth Darnall, PhD.

COMPLETED
Registry status
Phase 1
Development phase
93 participants
Enrollment target
1
Study location

Study Summary

Research shows that the immune system is involved in chronic pain. The immune system is involved in the process of inflammation. The investigators are still learning about the factors that cause inflammation, but know it can be measured in the blood. The purpose of this study is to understand how negative thoughts affect the immune system in women with chronic pain. A sub-study asks subjects to store a blood sample for future research by the PI aimed at identifying genetic markers in women with chronic pain.

Conditions Studied

Interventions

  • BEHAVIORAL Pain Catastrophizing Induction

Study Locations (1)

Oregon

  • Oregon Health and Science Universtiy - Portland

Trial Details

FieldValue
Enrollment Target 93 participants
Start Date 2009-01
Est. Completion 2014-09
Phase Phase 1
Beth Darnall, PhD

1 total trials

What the finished NCT00823147 record still lists

NCT00823147 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 93 participants, a relatively small participant target, below the 153-participant average among 37 other Musculoskeletal Pain trials with a reported enrollment target (39% lower).

The record links to 1 condition, with Musculoskeletal Pain appearing as the primary indexed condition, and to 1 intervention - of which Pain Catastrophizing Induction is the first listed.

NCT00823147 reports a single indexed study location in Oregon.

Frequently Asked Questions

What is clinical trial NCT00823147 about?

NCT00823147 is a clinical study titled "Pain Catastrophizing as a Cause for Systemic Inflammation". Research shows that the immune system is involved in chronic pain. The immune system is involved in the process of inflammation. The investigators are still learning about the factors that cause inflammation, but know it can be measured in the blood. The purpose of this study is to understand how ne...

What is the current status of trial NCT00823147?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 93 participants. The study started on 2009-01. Estimated completion is 2014-09.

What conditions does trial NCT00823147 study?

This clinical trial studies the following conditions: Musculoskeletal Pain.

What interventions are being tested in trial NCT00823147?

The interventions under investigation include: Pain Catastrophizing Induction (BEHAVIORAL).

Who is sponsoring clinical trial NCT00823147?

This trial is sponsored by Beth Darnall, PhD, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00823147 being conducted?

This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Musculoskeletal Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00823147's enrollment target sits among peer trials

93 19th of 37 higher than 19 of 37 other Musculoskeletal Pain trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Musculoskeletal Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02203526 · 93 participants · Phase 1

    Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma

  • NCT03089554 · 93 participants · Phase 2

    Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies

  • NCT05000021 · 93 participants · NA

    Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes

  • NCT05489887 · 93 participants · Phase 2

    Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00823147, the US trial registry maintained by the National Library of Medicine. NCT00823147 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.